Dexmedetomidine Prevents Postoperative Delirium After Awake Craniotomies
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Postoperative delirium (POD) is a common complication, and the incidence of POD ranges from
10% to 60%. Previous studies suggested that frontal approach and tumor located at the
temporal lobe were independent risk factors for POD after supratentorial tumor resections.
Therefore, patients undergoing awake craniotomies are high-risk populations for POD. A lot of
trials show that dexmedetomidine might help to reduce the incidence of delirium in patients
undergoing non-cardiac surgery. However, the impact of dexmedetomidine on POD for patients
undergoing awake craniotomies remains unclear. The purpose of this study was to investigate
the effect of DEX on POD in patients undergoing awake craniotomies.